“No, I never considered it was risky, and no, of course, I’m not getting paid. I just received my second shot a few days ago. “

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference. Piper Sandler 32nd Annual Virtual Healthcare Conference Panel Date: Tuesday, December 1, 2020 Time:10:00 a.m. Eastern Time (ET) Panel title:The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021 Moderators:Edward A. Tenthoff and Yasmeen Rahimi, Ph.D. NVAX Panelist:Gregory M. Glenn, M.D., President of Research and Development, Novavax Additional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc. This event is open to Piper Sandler clients    Conference  Event: Participants:Fireside chat Stanley C. Erck, President and Chief Executive Officer, and Dr. Glenn Webcast: A replay of the recorded fireside session is available through the events page of the Company’s website at ir.novavax.com for 90 days.    Event: Date: Investor meetings Wednesday, December 2, 2020 Evercore ISI 3rd Annual HealthCONx Conference Date:Thursday, December 3, 2020 Time:2:15 p.m. Eastern Time (ET) Participation:Fireside chat and investor meetings Live webcast:www.novavax.com, “Investors”/ “Events”    About NVX-CoV2373NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the U.K. and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $399 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and almost $1.7 billion from the U.S. government.        About Novavax Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.  Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.Contacts: Investors Erika Trahan ir@novavax.com 240-268-2022Media Brandzone/KOGS Communication Edna Kaplan kaplan@kogspr.com 617-974-8659

Top novel coronavirus stock Novavax (NASDAQ:NVAX) is ready to ramp. Wednesday’s session saw NVAX stock burst through resistance amid a rousing 8.3% rally. With little overhead resistance in the vicinity, this red-hot stock offers big profit potential heading into December. Source: Ascannio/Shutterstock.com To pre-qualify the trade idea I will unveil below, I must remind readers that Novavax is not a pick for the faint of heart. With the potential for monster gains comes the possibility of quick losses. If this year has taught NVAX speculators anything, it is that the size of your position matters greatly. It is far easier to ride a small position through tumultuous twists and turns than a large one.InvestorPlace – Stock Market News, Stock Advice & Trading Tips How We Got Here With NVAX Stock Novavax entered 2020 as a sub-$4 stock that absolutely no one watched. And that was after a 1-for-20 reverse split saved it from the shady land of penny stocks. Then, the novel coronavirus changed everything. Its entrance signaled the beginning of a race with the promise of rich rewards to the eventual winner. Of course, we are talking about the mad dash by biotech and drug companies around the globe to create and bring to market an effective vaccine. 10 Best Stocks to Buy for Investors Under 30 Wall Street quickly recognized NVAX stock as a promising frontrunner. And, as they are wont to do, investors bid prices of the once little-known nobody to the moon and beyond. The volatility, as you might expect, has been intense. After its initial burst stopped just shy of $200, prices were halved in August. Since then, it has been a rocky road to find the bottom. But if recent price action is any indication, I think we just found the low. Let’s take a closer look. NVAX Stock Chart Source: The thinkorswim® platform from TD Ameritrade The weekly chart chronicles the astounding ascent and late-year halving of Novavax’s share price. Two things of note stand out. First, we broke the 20-week moving average, signaling a weakening of the long-term uptrend. Second, although we carved out a lower pivot low last month, the downside momentum slowed. That suggests prices are finding a new equilibrium, and buyers are stepping in to stem what could have been a steeper decline. One added wrinkle to analyzing the price action for a biotech stock is the increased chance for adverse news that creates trend-killing gaps. For a company whose destiny hinges largely on how its vaccine trials fare, this is an ever-present risk for any NVAX trades. Moving down to the daily time frame shows greater detail on how the multi-month downtrend slowed this month. What caught my eye is a breakout attempt today over the 50-day moving average. This smoothing mechanism has been a useful guide for trend direction. Ever since we fell below it in August, rallies have been rejected, and downward pressure has remained. Source: The thinkorswim® platform from TD Ameritrade This week’s upswing succeeded where so many of its predecessors failed. A close above $100 will confirm the breakout and provide a reason for short-term traders and potentially long-term investors to turn bullish. Play It Smart With Bull Calls Because of the higher risk of sudden news and the potential for share prices to cascade lower, I prefer using a defined-risk options trade. The wild nature of NVAX stock translates into wider bid-ask spreads for options, so limit orders are a must for this play. Bull Call: Buy the Jan $110/$130 bull call spread for $4.70 The risk is limited to your initial cost of $4.70. The reward is capped at $15.30 and will be captured if NVAX stock rises past $130 by expiration. On the date of publication, Tyler Craig did not have (either directly or indirectly) any positions in the securities mentioned in this article. For a free trial to the best trading community on the planet and Tyler’s current home, click here! More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Novavax Stock Is Ready to Shoot Higher Again appeared first on InvestorPlace.

Right before we rang in 2020, Novavax (NASDAQ:NVAX) found its equity units trading for just under $4. Fast-forward a few months into the novel coronavirus pandemic and NVAX stock was screaming toward the $200 level. Source: Ascannio/Shutterstock.com Of course, it didn’t quite get there. However, if you had gambled on shares at the beginning of this year, you’re still doing very well. Indeed, it’s hard not to call Novavax as the Cinderella play of 2020. As the New York Times detailed, the biotechnology firm was on the verge of collapse. Before Covid-19 became top and center on everyone’s mind, Novavax was developing a vaccine to prevent a deadly virus in infants. Like other vaccine candidates in the company’s pipeline, it failed, drawing serious questions about the viability of NVAX stock.InvestorPlace – Stock Market News, Stock Advice & Trading Tips Therefore, in a strangely fortuitous and cynical way, the coronavirus was the best thing that happened to Novavax. I hate to phrase it like that, considering that Dr. Anthony Fauci recently warned us to “…do the math. Two to three thousand deaths a day times a couple of months, and you’re approaching a really stunning number of deaths.” 10 Best Stocks to Buy for Investors Under 30 Still, without the pandemic, NVAX stock was itself likely staring at a permanent departure. While this spared many stakeholders, another question has come up in the past few weeks: can Novavax stay relevant in the coronavirus vaccine race? It’s the question that’s one of the most frequently asked on Wall Street, now that Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and now AstraZeneca (NASDAQ:AZN) have each delivered reports indicating high effectiveness against Covid-19. Just as importantly, the safety profiles of each vaccine candidate is encouraging. Will this leave NVAX stock in the dust, with Novavax agonizingly short of the finish line? Initially, that’s the seemingly reasonable assumption. However, the vaccine race is more of a calculus problem than it is an elementary arithmetic challenge. NVAX Stock Is Still Relevant Despite Hiccups If the battle against the novel coronavirus simply amounted to forwarding a solution, then NVAX stock would probably not be your best bet. Frankly, neither would Pfizer’s nor Moderna’s candidate. Instead, the spoils would belong to the Russians and their Sputnik V vaccine. But for better or for worse, this race isn’t linear. Indeed, the non-linearity of the Covid-19 vaccination race is what keeps NVAX stock in the running, despite rivals charging first into the headlines. Mainly, this is because you can break down the race into three components: the science, the administration and the distribution. Interestingly, none of the vaccine candidates – whether in advanced trials or stuck in the pre-clinical phase – offer a comprehensively viable solution. For instance, the underlying science of Pfizer and Moderna is incredibly compelling. Both have forwarded messenger-RNA-based vaccines, which offer quick manufacturing capabilities. Naturally, this is a huge advantage, especially when the world hungers for a robust and safe solution. However, one of the main draw backs of nucleic-acid-based vaccines (to which RNA vaccines belong) is that they’ve never been approved by the Food and Drug Administration. Broadly speaking, human safety trials, though encouraging are limited. More critically, the stability of mRNA is a matter of ongoing research, which could mean that long-term immunogenicity may be impacted. On the other hand, Novavax utilizes a subunit vaccine, which is a proven platform. For example, the hepatitis B vaccine came about because of research with subunits. Also, the New England Journal of Medicine analyzed Novavax’s candidate NVX-CoV2373 and discovered encouraging data on efficacy. Should investors then jump on NVAX stock as a contrarian play off the attention given to Pfizer and Moderna? Not quite. All three score unfavorably on the administration front as they will likely require two doses to be truly effective. That said, Novavax may have an edge in terms of distribution, as Pfizer’s/Moderna’s vaccines may need frozen storage. But again, this doesn’t mean that Novavax is a better solution for Covid-19. As I mentioned in September, the “manufacturing process to develop the underlying nanoparticles is more involved than producing the traditional oligonucleotides that may be used in nucleic-acid vaccines.” As you know, time is of the essence. Demographics Will Be Key Given that the current coronavirus vaccines have a range of shortcomings, the approach moving forward will be to focus on each candidate’s strengths. From there, health officials can strategize which vaccines go where. For instance, some health care facilities in the U.S. may not have the infrastructure to handle freezing storage requests. That could make vaccines from Pfizer and Moderna inappropriate. However, it would open the door to Novavax, AstraZeneca or even Johnson & Johnson (NYSE:JNJ), which utilizes a viral-vector approach similar to AZN. Also, another consideration could be age and the existence of underlying conditions. In my opinion, RNA-based vaccines seem best suited for younger or healthier individuals. In contrast, subunit vaccines are applicable to people with weakened immune systems. Thus, you could see Novavax’s candidate heading toward states with higher levels of chronic conditions. Ultimately, the biggest takeaway is that the United States is the greatest country in the world. And President Donald Trump deserves credit for spearheading an unprecedented initiative that seems to have resulted in a massive success. But this victory isn’t exclusive to any one company, which keeps NVAX stock in the game. On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Overlook Novavax at the Risk of Incurring an Opportunity Cost appeared first on InvestorPlace.

With three vaccine candidates out with a first look at efficacy data, Wall Street is more optimistic about the light at the end of the pandemic tunnel.